Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Hepatocellular Carcinoma | Research

Transcriptional analysis of the expression and prognostic value of lipid droplet-localized proteins in hepatocellular carcinoma

Authors: Yize Zhang, Xue Liang, Qinghai Lian, Liwen Liu, Baoyu Zhang, Zihui Dong, Kunpeng Liu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

The accumulation of lipid droplets (LDs) in hepatocytes is the main pathogenesis in nonalcoholic fatty liver disease (NAFLD), which is also the key risk factor for the progression of hepatocellular carcinoma (HCC). LDs behaviors are demonstrated to be associated with HCC advancement, and are tightly regulated by a subset protein localized on the surface of LDs. However, the role of LDs-localized protein in HCC has been rarely investigated. This study is focused on the transcriptional dynamic and prognostic value of LDs-localized protein in HCC. Firstly, we summarized the known LDs-localized proteins, which are demonstrated by immunofluorescence according to previous studies. Next, by the use of GEPIA/UALCAN/The Human Protein Atlas databases, we screened the transcriptional change in tumor and normal liver tissues, and found that 13 LDs-localized proteins may involve in the progression of HCC. Then we verified the transcriptional changes of 13 LDs-localized proteins by the use of HCC samples. Moreover, based on the assays of fatty liver of mice and human NAFLD liver samples, we found that the hepatic steatosis mainly contributed to the transcriptional change of selected LDs-localized proteins, indicating the involvement of these LDs-localized proteins in the negative role of NAFLD in HCC progression. Finally, we focused on the role of PLIN3 in HCC, and revealed that NAFLD status significantly promoted PLIN3 transcription in HCC tissue. Functional studies revealed that PLIN3 knockdown significantly limited the migration and chemosensitivity of hepatoma cells, suggesting the positive role of PLIN3 in HCC progression. Our study not only revealed the transcriptional change and prognostic value of lipid droplet-localized proteins in HCC, but also built the correlation between HCC and hepatic steatosis.
Appendix
Available only for authorised users
Literature
1.
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(1):4–13.CrossRefPubMed
2.
Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear C, Younossi Z. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine. 2017;96(9):e5904.CrossRefPubMedPubMedCentral
3.
Yip T, Lee H, Chan W, Wong G, Wong V. Asian perspective on NAFLD-associated HCC. J Hepatol. 2022;76(3):726–34.CrossRefPubMed
4.
Ertle J, Dechêne A, Sowa J, Penndorf V, Herzer K, Kaiser G, Schlaak J, Gerken G, Syn W, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128(10):2436–43.CrossRefPubMed
5.
Cholankeril G, Patel R, Khurana S, Satapathy S. Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management. World J Hepatol. 2017;9(11):533–43.CrossRefPubMedPubMedCentral
6.
Kanwal F, Kramer J, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson P, Li L, Desiderio R, Thrift A, Asch S, et al. Risk of Hepatocellular Cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828–1837e1822.CrossRefPubMed
7.
Younossi Z, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology (Baltimore MD). 2015;62(6):1723–30.CrossRefPubMed
8.
Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56(4):952–64.CrossRefPubMed
9.
Hu B, Lin JZ, Yang XB, Sang XT. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: a review. Cell Prolif. 2020;53(3):e12772.CrossRefPubMedPubMedCentral
10.
Seebacher F, Zeigerer A, Kory N, Krahmer N. Hepatic lipid droplet homeostasis and fatty liver disease. Semin Cell Dev Biol. 2020;108:72–81.CrossRefPubMed
11.
Chen K, Ma J, Jia X, Ai W, Ma Z, Pan Q. Advancing the understanding of NAFLD to hepatocellular carcinoma development: from experimental models to humans. Biochim et Biophys acta Reviews cancer. 2019;1871(1):117–25.CrossRef
12.
13.
Corbet C, Bastien E, Santiago de Jesus J, Dierge E, Martherus R, Vander Linden C, Doix B, Degavre C, Guilbaud C, Petit L, et al. TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 2020;11(1):454.CrossRefPubMedPubMedCentral
14.
Cotte A, Aires V, Fredon M, Limagne E, Derangère V, Thibaudin M, Humblin E, Scagliarini A, de Barros J, Hillon P, et al. Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance. Nat Commun. 2018;9(1):322.CrossRefPubMedPubMedCentral
15.
Berndt N, Eckstein J, Heucke N, Gajowski R, Stockmann M, Meierhofer D, Holzhütter H. Characterization of lipid and lipid droplet metabolism in Human HCC. Cells 2019, 8(5).
16.
Yang L, Ding Y, Chen Y, Zhang S, Huo C, Wang Y, Yu J, Zhang P, Na H, Zhang H, et al. The proteomics of lipid droplets: structure, dynamics, and functions of the organelle conserved from bacteria to humans. J Lipid Res. 2012;53(7):1245–53.CrossRefPubMedPubMedCentral
17.
Bersuker K, Peterson C, To M, Sahl S, Savikhin V, Grossman E, Nomura D, Olzmann J. A proximity labeling strategy provides insights into the Composition and Dynamics of lipid droplet proteomes. Dev Cell. 2018;44(1):97–112e117.CrossRefPubMed
18.
Petan T. Lipid Droplets in Cancer. Reviews of physiology, biochemistry and pharmacology 2020.
19.
Cruz A, Barreto E, Fazolini N, Viola J, Bozza P. Lipid droplets: platforms with multiple functions in cancer hallmarks. Cell Death Dis. 2020;11(2):105.CrossRefPubMedPubMedCentral
20.
Ndiaye H, Liu J, Hall A, Minogue S, Morgan M, Waugh M. Immunohistochemical staining reveals differential expression of ACSL3 and ACSL4 in hepatocellular carcinoma and hepatic gastrointestinal metastases. Biosci Rep 2020, 40(4).
21.
Chen J, Zhuo J, Yang F, Liu Z, Zhou L, Xie H, Xu X, Zheng S. 17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma. Hepatobiliary & pancreatic diseases international: HBPD INT. 2018;17(3):220–6.CrossRef
22.
Zhang Y, Pan Q, Yu Y, Zhong X. microRNA-519d induces autophagy and apoptosis of human hepatocellular carcinoma cells through activation of the AMPK Signaling Pathway via Rab10. Cancer Manage Res. 2020;12:2589–602.CrossRef
23.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102.CrossRefPubMedPubMedCentral
24.
Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B, Varambally S. UALCAN: a portal for facilitating Tumor Subgroup Gene expression and survival analyses. Neoplasia (New York NY). 2017;19(8):649–58.CrossRef
25.
Liu X, Zhang Y, Wang Z, Liu L, Zhang G, Li J, Ren Z, Dong Z, Yu Z. PRRC2A promotes Hepatocellular Carcinoma Progression and Associates with Immune Infiltration. J hepatocellular carcinoma. 2021;8:1495–511.CrossRef
26.
Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discovery. 2016;15(4):249–74.CrossRefPubMed
27.
Bersuker K, Olzmann J. Establishing the lipid droplet proteome: mechanisms of lipid droplet protein targeting and degradation. Biochim et Biophys acta Mol cell biology lipids. 2017;1862:1166–77.CrossRef
28.
Kimmel A, Brasaemle D, McAndrews-Hill M, Sztalryd C, Londos C. Adoption of PERILIPIN as a unifying nomenclature for the mammalian PAT-family of intracellular lipid storage droplet proteins. J Lipid Res. 2010;51(3):468–71.CrossRefPubMedPubMedCentral
29.
Masuda Y, Itabe H, Odaki M, Hama K, Fujimoto Y, Mori M, Sasabe N, Aoki J, Arai H, Takano T. ADRP/adipophilin is degraded through the proteasome-dependent pathway during regression of lipid-storing cells. J Lipid Res. 2006;47(1):87–98.CrossRefPubMed
30.
Bulankina A, Deggerich A, Wenzel D, Mutenda K, Wittmann J, Rudolph M, Burger K, Höning S. TIP47 functions in the biogenesis of lipid droplets. J Cell Biol. 2009;185(4):641–55.CrossRefPubMedPubMedCentral
31.
Skinner J, Shew T, Schwartz D, Tzekov A, Lepus C, Abumrad N, Wolins N. Diacylglycerol enrichment of endoplasmic reticulum or lipid droplets recruits perilipin 3/TIP47 during lipid storage and mobilization. J Biol Chem. 2009;284(45):30941–8.CrossRefPubMedPubMedCentral
32.
Carr R, Patel R, Rao V, Dhir R, Graham M, Crooke R, Ahima R. Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice. Am J Physiol Regul Integr Comp Physiol. 2012;302(8):R996–1003.CrossRefPubMedPubMedCentral
33.
Ferguson D, Zhang J, Davis M, Helsley R, Vedin L, Lee R, Crooke R, Graham M, Allende D, Parini P, et al. The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis. J Lipid Res. 2017;58(2):420–32.CrossRefPubMedPubMedCentral
34.
Wang K, Ruan H, Song Z, Cao Q, Bao L, Liu D, Xu T, Xiao H, Wang C, Cheng G, et al. PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma. Urol Oncol. 2018;36(7):343e319–49.CrossRef
35.
Szigeti A, Minik O, Hocsak E, Pozsgai E, Boronkai A, Farkas R, Balint A, Bodis J, Sumegi B, Bellyei S. Preliminary study of TIP47 as a possible new biomarker of cervical dysplasia and invasive carcinoma. Anticancer Res. 2009;29(2):717–24.PubMed
36.
Zhou L, Song Z, Hu J, Liu L, Hou Y, Zhang X, Yang X, Chen K. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3. Theranostics. 2021;11(2):841–60.CrossRefPubMedPubMedCentral
37.
Dupont N, Chauhan S, Arko-Mensah J, Castillo E, Masedunskas A, Weigert R, Robenek H, Proikas-Cezanne T, Deretic V. Neutral lipid stores and lipase PNPLA5 contribute to autophagosome biogenesis. Curr biology: CB. 2014;24(6):609–20.CrossRefPubMed
38.
Kaushik S, Cuervo A. Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. Nat Cell Biol. 2015;17(6):759–70.CrossRefPubMedPubMedCentral
39.
Metadata
Title
Transcriptional analysis of the expression and prognostic value of lipid droplet-localized proteins in hepatocellular carcinoma
Authors
Yize Zhang
Xue Liang
Qinghai Lian
Liwen Liu
Baoyu Zhang
Zihui Dong
Kunpeng Liu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10987-z

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

The potential of high-order features of routine blood test in predicting the prognosis of non-small cell lung cancer

Research

Association of high-risk comorbidity with overall survival among patients with gastric cancer and its sex-specific differences in China: a retrospective observational cohort study

Research

Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany

Study Protocol

Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial

Research

Pan-cancer analysis of whole-genome doubling and its association with patient prognosis

Research

Predictors and characteristics of Rib fracture following SBRT for lung tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits